Confused why people are calling PP405 a cure...it never claimed to be able to undo miniaturization or revert vellus back to terminal hairs. It seems to be more of a growth stimulant like minoxidil.
    Research/Science 1/5/2025

    From the encyclopedia
    PP405 →

    mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    At a glance
    In this general discussion post, the primary subjects mentioned are the tone is 😐 neutral.

    Other terms

    PP405 is not a cure for hair loss but may reactivate dormant hair follicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results
      Recent Advances in Drug Development for Hair Loss

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
      PP405 in Alopecia: An Emerging Molecule Worth Investigating

      research PP405 in Alopecia: An Emerging Molecule worth Investigating

      January 2026 in “Journal of Community Medicine and Health Solutions”
      In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

      research Emerging pharmacotherapies for Androgenetic Alopecia

      June 2026 in “Expert Opinion on Pharmacotherapy”
      This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.